# Expansion and cytotoxicity of mucosal CAR + T cells in enterocolitis associated with BCMA CAR-T cell therapy

Source: [nature.com](https://www.nature.com/articles/s41591-026-04731-w) · 2026-11-19 · Medicine
Page: https://themorning.science/story/expansion-and-cytotoxicity-of-mucosal-car-t-cells-in-enterocolitis-associated-wi-bfddc1b9752290be
Kind: research · Impact: medium

## In brief

- Two Nature Medicine papers published 19 November 2026 characterise immune effector cell-associated enterocolitis after BCMA-directed CAR T cell therapy.
- One study uses multimodal profiling of biopsy-confirmed cases after ciltacabtagene autoleucel, reporting that CAR T cell infiltrates are concentrated in the gut mucosa.
- A larger multicenter case series reports that only 32% of patients who developed the enterocolitis had achieved disease response.

## Why it matters

The studies describe a serious gastrointestinal complication of a widely used cancer immunotherapy, which helps clinicians recognise and characterise it in patients receiving BCMA CAR T cells.

## Timeline

- 2026-11-19: Both studies published online in Nature Medicine (doi:10.1038/s41591-026-04731-w and doi:10.1038/s41591-026-04783-y)

## Coverage

- [Expansion and cytotoxicity of mucosal CAR + T cells in enterocolitis associated with BCMA CAR-T cell therapy](https://www.nature.com/articles/s41591-026-04731-w) — nature.com, 2026-11-19
- [Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy](https://www.nature.com/articles/s41591-026-04783-y) — nature.com, 2026-11-19

Tags: car t cells, bcma, enterocolitis, immunotherapy, multiple myeloma, adverse events

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
